Analyst Reco. Jazz Pharmaceuticals plc Sao Paulo

Equities

J2AZ34

BRJ2AZBDR009

Market Closed - Sao Paulo Other stock markets 09:17:51 2024-05-10 EDT			5-day change	1st Jan Change
38.72 ^BRL	-0.56%		-.--%	-10.95%

06-20	Needham Adjusts Price Target on Jazz Pharmaceuticals to $210 From $222, Maintains Buy Rating	MT
06-20	Sector Update: Health Care Stocks Lean Lower Pre-Bell Thursday	MT

Analyst Reco.

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Needham Adjusts Price Target on Jazz Pharmaceuticals to $210 From $222, Maintains Buy Rating	06-20	MT
Jazz Pharmaceuticals Insider Sold Shares Worth $548,250, According to a Recent SEC Filing	05-07	MT
UBS Adjusts Price Target on Jazz Pharmaceuticals to $117 From $121, Maintains Neutral Rating	05-03	MT
JPMorgan Raises Jazz Pharmaceuticals' Price Target to $190 From $170, Maintains Overweight Rating	03-25	MT
Piper Sandler Adjusts Price Target on Jazz Pharmaceuticals to $188 From $171, Maintains Overweight Rating	03-20	MT
Stifel Raises Jazz Pharmaceuticals' Price Target to $230 From $225, Maintains Buy Rating	03-15	MT
H.C. Wainwright Cuts Price Target on Jazz Pharmaceuticals to $200 From $204, Maintains Buy Rating	03-14	MT
UBS Adjusts Jazz Pharmaceuticals Price Target to $131 From $135, Maintains Neutral Rating	03-01	MT
Barclays Cuts Price Target on Jazz Pharmaceuticals to $230 From $235, Maintains Overweight Rating	03-01	MT
Needham Cuts Price Target on Jazz Pharmaceuticals to $220 From $225, Maintains Buy Rating	02-29	MT
Barclays Adjusts Jazz Pharmaceuticals' Price Target to $235 From $240, Keeps Overweight Rating	01-29	MT
RBC Raises Price Target on Jazz Pharmaceuticals to $195 From $191, Keeps Outperform Rating	01-03	MT
Baird Initiates Jazz Pharmaceuticals With Outperform Rating, Price Target is $160	01-03	MT
UBS Downgrades Jazz Pharmaceuticals to Neutral From Buy, Adjusts Price Target to $135 From $170	11-27	MT
Needham Adjusts Jazz Pharmaceuticals' Price Target to $225 From $226, Maintains Buy Rating	11-09	MT
RBC Cuts Price Target on Jazz Pharmaceuticals to $191 From $200, Keeps Outperform Rating	11-09	MT
Raymond James Initiates Jazz Pharmaceuticals With Market Perform Rating	23-09-29	MT
Cantor Fitzgerald Cuts Jazz Pharmaceuticals' Price Target to $180 From $210, Keeps Overweight Rating	23-08-14	MT
Cantor Fitzgerald Cuts Price Target on Jazz Pharmaceuticals to $180 From $210, Maintains Overweight Rating	23-08-14	MT
RBC Trims Price Target on Jazz Pharmaceuticals to $201 From $203, Keeps Outperform Rating	23-08-10	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Analyst Reco. Jazz Pharmaceuticals plc Sao Paulo

Equities

J2AZ34

BRJ2AZBDR009

Analyst Reco.

Filters